赛升药业：马丽和刘淑芹计划减持公司股份合计不超过约963万股

Core Viewpoint - The announcement from Sai Sheng Pharmaceutical indicates that two significant shareholders plan to reduce their holdings, which may impact the company's stock performance and investor sentiment [1] Group 1: Shareholder Actions - Ms. Ma Li holds approximately 29.85 million shares, accounting for 6.2% of the total share capital of about 482 million shares [1] - Ms. Liu Shuqin holds approximately 8.75 million shares, representing 1.82% of the total share capital [1] - Both shareholders plan to reduce their combined holdings by up to approximately 9.63 million shares, not exceeding 2% of the total share capital, within three months after the announcement [1] Group 2: Company Financials - For the year 2024, the revenue composition of Sai Sheng Pharmaceutical is projected to be 99.63% from the pharmaceutical manufacturing sector and 0.37% from other businesses [1] - As of the announcement, the market capitalization of Sai Sheng Pharmaceutical is 5.8 billion yuan [1]